<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39339257</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Aerosol of Enoximone/Hydroxypropyl-β-Cyclodextrin Inclusion Complex, Biopharmaceutical Evidence for ARDS Applicability.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1221</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16091221</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Phosphodiesterase (PDE) inhibitors are gaining interest in the context of pulmonary pathologies. In particular, the PDE3 inhibitor enoximone (ENXM) has shown potential relative to the cure of asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS). Despite its administration via inhalation being planned for use against COVID-19 related ARDS (C-ARDS), presently, no inhalable medicine containing ENXM is available.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to develop a new formulation suitable for pulmonary administration of ENXM.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A solution for nebulization, based on the complex between ENXM and Hydroxypropyl-β-Cyclodextrin (HPβCD) (ENXM/HPβCD) is developed. The obtained solution is characterized in terms of aerodynamic distributions and biopharmaceutical features.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The evaluation of the aerosol droplets indicates a good bronchi-lung distribution of the drug. Biological evaluations of the air-liquid interface (ALI) in an in vitro lung cell model demonstrates that ENXM/HPβCD is capable of a local direct effect, increasing intracellular cyclic adenosine monophosphate (cAMP) levels and protecting from oxidative stress.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study offers a promising advance in the optimization of enoximone delivery to the lungs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Migone</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassiri</LastName><ForeName>Brunella</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6404-9845</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizzoni</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0009-1045-005X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Life Sciences, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabiano</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3912-840X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferro</LastName><ForeName>Baldassare</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Anestesia e Rianimazione, Azienda USL Toscana Nord Ovest, 57124 Livorno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambito</LastName><ForeName>Ylenia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0064-233X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piras</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-4082-6400</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Instrument Sharing of University of Pisa (CISUP), 56126 Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>This research was funded by Regione Toscana, Ministero della Università e della Ricerca della Repubblica Italiana,- PAR FSC 2007-2013, AEROPLAS-19 CUP I55F20000600007, Italy.</GrantID><Agency>This research was funded by Regione Toscana, Ministero della Università e della Ricerca della Repubblica Italiana,- PAR FSC 2007-2013, AEROPLAS-19 CUP I55F20000600007, Italy.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">anti-inflammatory activity</Keyword><Keyword MajorTopicYN="N">cAMP</Keyword><Keyword MajorTopicYN="N">enoximone</Keyword><Keyword MajorTopicYN="N">hydroxypropyl-β-cyclodextrin</Keyword><Keyword MajorTopicYN="N">inhalation</Keyword><Keyword MajorTopicYN="N">lung in vitro model</Keyword><Keyword MajorTopicYN="N">oxidative stress protection</Keyword><Keyword MajorTopicYN="N">phosphodiesterase-3 inhibitor</Keyword><Keyword MajorTopicYN="N">pulmonary delivery</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339257</ArticleId><ArticleId IdType="pmc">PMC11435411</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16091221</ArticleId><ArticleId IdType="pii">pharmaceutics16091221</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rizzo A.N., Aggarwal N.R., Thompson B.T., Schmidt E.P. Advancing Precision Medicine for the Diagnosis and Treatment of Acute Respiratory Distress Syndrome. J. Clin. Med. 2023;12:1563. doi: 10.3390/jcm12041563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12041563</ArticleId><ArticleId IdType="pmc">PMC9966442</ArticleId><ArticleId IdType="pubmed">36836098</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Arabi Y., Arroliga A.C., Bernard G., Bersten A.D., Brochard L.J., Calfee C.S., Combes A., Daniel B.M., Ferguson N.D., et al. A New Global Definition of Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care. Med. 2024;209:37–47. doi: 10.1164/rccm.202303-0558WS.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202303-0558WS</ArticleId><ArticleId IdType="pmc">PMC10870872</ArticleId><ArticleId IdType="pubmed">37487152</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D. Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies. J. Clin. Med. 2023;12:1381. doi: 10.3390/jcm12041381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12041381</ArticleId><ArticleId IdType="pmc">PMC9967510</ArticleId><ArticleId IdType="pubmed">36835919</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizzoni L., Migone C., Grassiri B., Zambito Y., Ferro B., Roncucci P., Mori F., Salvatore A., Ascione E., Crea R., et al. Biopharmaceutical Assessment of Mesh Aerosolised Plasminogen, a Step towards ARDS Treatment. Pharmaceutics. 2023;15:1618. doi: 10.3390/pharmaceutics15061618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15061618</ArticleId><ArticleId IdType="pmc">PMC10300680</ArticleId><ArticleId IdType="pubmed">37376068</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Taskinen J.H., Segersvärd H., Immonen K., Kosonen R., Tolva J.M., Mäyränpää M.I., Kovanen P.T., Olkkonen V.M., Sinisalo J., et al. Alterations of Cardiac Protein Kinases in Cyclic Nucleotide-Dependent Signaling Pathways in Human Ischemic Heart Failure. Front. Cardiovasc. Med. 2022;9:919355. doi: 10.3389/fcvm.2022.919355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.919355</ArticleId><ArticleId IdType="pmc">PMC9247256</ArticleId><ArticleId IdType="pubmed">35783854</ArticleId></ArticleIdList></Reference><Reference><Citation>Calamera G., Moltzau L.R., Levy F.O., Andressen K.W. Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts. Int. J. Mol. Sci. 2022;23:2145. doi: 10.3390/ijms23042145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23042145</ArticleId><ArticleId IdType="pmc">PMC8880502</ArticleId><ArticleId IdType="pubmed">35216259</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsesian M., Ahmad F., Hirsch E. Functions of PDE3 Isoforms in Cardiac Muscle. J. Cardiovasc. Dev. Dis. 2018;5:10. doi: 10.3390/jcdd5010010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd5010010</ArticleId><ArticleId IdType="pmc">PMC5872358</ArticleId><ArticleId IdType="pubmed">29415428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo H., Cattani-Cavalieri I., Musheshe N., Nikolaev V.O., Schmidt M. Phosphodiesterases as Therapeutic Targets for Respiratory Diseases. Pharmacol. Ther. 2019;197:225–242. doi: 10.1016/j.pharmthera.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2019.02.002</ArticleId><ArticleId IdType="pubmed">30759374</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A.J., Vorla M., Kalra D.K. Molecular Pathways in Pulmonary Arterial Hypertension. Int. J. Mol. Sci. 2022;23:10001. doi: 10.3390/ijms231710001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231710001</ArticleId><ArticleId IdType="pmc">PMC9456336</ArticleId><ArticleId IdType="pubmed">36077398</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin D. ABCD of the Phosphodiesterase Family: Interaction and Differential Activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008;3:543–561. doi: 10.2147/COPD.S1761.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S1761</ArticleId><ArticleId IdType="pmc">PMC2650605</ArticleId><ArticleId IdType="pubmed">19281073</ArticleId></ArticleIdList></Reference><Reference><Citation>Crilley T.K., Wanstall J.C., Bonnet P. Vasorelaxant Effects of SCA40 (A Phosphodiesterase III Inhibitor) in Pulmonary Vascular Preparations in Rats. Clin. Exp. Pharmacol. Physiol. 1998;25:355–360. doi: 10.1111/j.1440-1681.1998.tb02363.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1681.1998.tb02363.x</ArticleId><ArticleId IdType="pubmed">9612663</ArticleId></ArticleIdList></Reference><Reference><Citation>Joskova M., Mokry J., Franova S. Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors. Front. Pharmacol. 2020;11:609. doi: 10.3389/fphar.2020.00609.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00609</ArticleId><ArticleId IdType="pmc">PMC7218135</ArticleId><ArticleId IdType="pubmed">32435198</ArticleId></ArticleIdList></Reference><Reference><Citation>Beute J., Ganesh K., Nastiti H., Hoogenboom R., Bos V., Folkerts J., Schreurs M.W.J., Hockman S., Hendriks R.W., KleinJan A. PDE3 Inhibition Reduces Epithelial Mast Cell Numbers in Allergic Airway Inflammation and Attenuates Degranulation of Basophils and Mast Cells. Front. Pharmacol. 2020;11:470. doi: 10.3389/fphar.2020.00470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00470</ArticleId><ArticleId IdType="pmc">PMC7206980</ArticleId><ArticleId IdType="pubmed">32425769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosutova P., Mikolka P., Mokra D., Calkovska A. Anti-inflammatory Activity of Non-selective PDE Inhibitor Aminophylline on the Lung Tissue and Respiratory Parameters in Animal Model of ARDS. J. Inflamm. 2023;20:10. doi: 10.1186/s12950-023-00337-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-023-00337-y</ArticleId><ArticleId IdType="pmc">PMC10018984</ArticleId><ArticleId IdType="pubmed">36927675</ArticleId></ArticleIdList></Reference><Reference><Citation>Milara J., Navarro A., Almudéver P., Lluch J., Morcillo E.J., Cortijo J. Oxidative Stress-Induced Glucocorticoid Resistance is Prevented by Dual PDE3/PDE4 Inhibition in Human Alveolar Macrophages. Clin. Exp. Allergy. 2011;41:535–546. doi: 10.1111/j.1365-2222.2011.03715.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2222.2011.03715.x</ArticleId><ArticleId IdType="pubmed">21395877</ArticleId></ArticleIdList></Reference><Reference><Citation>Beute J. Use of Enoximone in the Treatment of Atopic Immune-Related Disorders, in Pharmaceutical Composition as Well As in Pharmaceutical Preparation. European Patent Office; Munich, Germany: 2017. (EP3131545A2).</Citation></Reference><Reference><Citation>Beute J., KleinJan A. Oral Enoximone Allows the Reduction and Discontinuation of Inhaled Steroids and Beta2 Agonists in Asthmatic Children. Int. J. Pediatr. Adolesc. Med. 2022;9:147–151. doi: 10.1016/j.ijpam.2021.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpam.2021.02.002</ArticleId><ArticleId IdType="pmc">PMC9152565</ArticleId><ArticleId IdType="pubmed">35663792</ArticleId></ArticleIdList></Reference><Reference><Citation>Beute J., Boermans P., Benraad B., Telman J., Diamant Z., KleinJan A. PDE3-Inhibitor Enoximone Prevented Mechanical Ventilation in Patients with SARS-CoV-2 Pneumonia. Exp. Lung Res. 2021;47:1–12. doi: 10.1080/01902148.2021.1881189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01902148.2021.1881189</ArticleId><ArticleId IdType="pmc">PMC7876671</ArticleId><ArticleId IdType="pubmed">33544007</ArticleId></ArticleIdList></Reference><Reference><Citation>Beute J., Boermans P., KleinJan A. Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. Can. Respir. J. 2021;2021:1–14. doi: 10.1155/2021/7456208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/7456208</ArticleId><ArticleId IdType="pmc">PMC8575614</ArticleId><ArticleId IdType="pubmed">34760031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro B., Cinelli R., Vegnuti L., Piras A.M., Roncucci P. The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report. J Aerosol Med Pulm Drug Deliv. 2021;34:262–264. doi: 10.1089/jamp.2021.0024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jamp.2021.0024</ArticleId><ArticleId IdType="pubmed">34152840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kali G., Haddadzadegan S., Bernkop-Schnürch A. Cyclodextrins and Derivatives in Drug Delivery: New Developments, Relevant Clinical Trials, and Advanced Products. Carbohydr. Polym. 2024;324:121500. doi: 10.1016/j.carbpol.2023.121500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2023.121500</ArticleId><ArticleId IdType="pubmed">37985088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadade D.D., Pekamwar S.S. Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics. Adv. Pharm. Bull. 2020;10:166–183. doi: 10.34172/apb.2020.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/apb.2020.022</ArticleId><ArticleId IdType="pmc">PMC7191229</ArticleId><ArticleId IdType="pubmed">32373486</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilcer G., Amighi K. Formulation Strategy and Use of Excipients in Pulmonary Drug Delivery. Int. J. Pharm. 2010;392:1–19. doi: 10.1016/j.ijpharm.2010.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.03.017</ArticleId><ArticleId IdType="pubmed">20223286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Liu Y., Pan P., Huang Y., Chen T., Yuan T., Ma Y., Han G., Li J., Jin Y., et al. Pulmonary Delivery of Resveratrol-β-Cyclodextrin Inclusion Complexes for the Prevention of Zinc Chloride Smoke-Induced Acute Lung Injury. Drug Deliv. 2022;29:1122–1131. doi: 10.1080/10717544.2022.2048135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10717544.2022.2048135</ArticleId><ArticleId IdType="pmc">PMC8986301</ArticleId><ArticleId IdType="pubmed">35380089</ArticleId></ArticleIdList></Reference><Reference><Citation>Alboni S., Secco V., Papotti B., Vilella A., Adorni M.P., Zimetti F., Schaeffer L., Tascedda F., Zoli M., Leblanc P., et al. Hydroxypropyl-β-Cyclodextrin Depletes Membrane Cholesterol and Inhibits SARS-CoV-2 Entry into HEK293T-ACEhi Cells. Pathogens. 2023;12:647. doi: 10.3390/pathogens12050647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12050647</ArticleId><ArticleId IdType="pmc">PMC10224288</ArticleId><ArticleId IdType="pubmed">37242317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Huang X., Sun Y., Lu G., Wang K., Wang Z., Xing J., Gao Y. Improvement of Pulmonary Absorption of Poorly Absorbable Macromolecules by Hydroxypropyl-β-Cyclodextrin Grafted Polyethylenimine (HP-β-CD-PEI) in Rats. Int. J. Pharm. 2015;489:294–303. doi: 10.1016/j.ijpharm.2015.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2015.05.020</ArticleId><ArticleId IdType="pubmed">25959121</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewes F., Brillault J., Couet W., Olivier J.-C. Formulation of Rifampicin–Cyclodextrin Complexes for Lung Nebulization. J. Control. Release. 2008;129:93–99. doi: 10.1016/j.jconrel.2008.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2008.04.007</ArticleId><ArticleId IdType="pubmed">18514353</ArticleId></ArticleIdList></Reference><Reference><Citation>Evrard B., Bertholet P., Gueders M., Flament M.-P., Piél G., Delattre L., Gayot A., Leterme P., Foidart J., Cataldo D. Cyclodextrins as a Potential Carrier in Drug Nebulization. J. Control. Release. 2004;96:403–410. doi: 10.1016/j.jconrel.2004.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2004.02.010</ArticleId><ArticleId IdType="pubmed">15120897</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP)  Questions and Answers on Cyclodextrins Used as Excipients in Medicinal Products for Human Use, EMA/CHMP/495747/2013.  [(accessed on 9 October 2017)].  Available online:  https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP)  In Report Published in Support of the ‘Questions and Answers on Cyclodextrins Used as Excipients in Medicinal Products for Human Use’ (EMA/CHMP/495747/2013). EMA/CHMP/333892/2013 Committee for Human Medicinal Products (CHMP)  [(accessed on 9 October 2017)].  Available online:  https://www.ema.europa.eu/en/documents/report/cyclodextrins-used-excipients-report-published-support-questions-and-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf.</Citation></Reference><Reference><Citation>Albert M.-A., Rocks N., Ait Mahmoude N., Petit L., Maes P., Cataldo D. Late Breaking Abstract—An innovative inhaled solution of budesonide-cyclodextrin complex is safe and prevents the methacholine-induced hyperreactivity in asthmatics better than a commercial budesonide suspension: A breezy story (BOREAS); Proceedings of the ERS International Congress; Milan, Italy. 9–13 September 2023.</Citation></Reference><Reference><Citation>Job P. Formation and Stability of Inorganic Complexes in Solution. Ann. Chim. 1928;9:113–203.</Citation></Reference><Reference><Citation>Grassiri B., Knoll P., Fabiano A., Piras A.M., Zambito Y., Bernkop-Schnürch A. Thiolated Hydroxypropyl-β-cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery. Int. J. Mol. Sci. 2022;23:2612. doi: 10.3390/ijms23052612.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052612</ArticleId><ArticleId IdType="pmc">PMC8910138</ArticleId><ArticleId IdType="pubmed">35269753</ArticleId></ArticleIdList></Reference><Reference><Citation>European Pharmacopoeia . Preparations for Inhalation: Aerodynamic Assessment of Fine Particles. Volume E. Council of Europe; Strasbourg, France: 2014. pp. 276–286.</Citation></Reference><Reference><Citation>Cidem A., Bradbury P., Traini D., Ong H.X. Modifying and Integrating in vitro and ex vivo Respiratory Models for Inhalation Drug Screening. Front. Bioeng. Biotechnol. 2020;8:581995. doi: 10.3389/fbioe.2020.581995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2020.581995</ArticleId><ArticleId IdType="pmc">PMC7644812</ArticleId><ArticleId IdType="pubmed">33195144</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolfa I., Page C. Phosphodiesterase inhibitors and lung diseases. Adv. Pharmacol. 2023;98:55–81. doi: 10.1016/bs.apha.2023.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.apha.2023.05.001</ArticleId><ArticleId IdType="pubmed">37524492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hye T., Moinuddin S.M., Sarkar T., Nguyen T., Saha D., Ahsan F. An evolving perspective on novel modified release drug delivery systems for inhalational therapy. Expert Opin. Drug Deliv. 2023;20:335–348. doi: 10.1080/17425247.2023.2175814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2023.2175814</ArticleId><ArticleId IdType="pmc">PMC10699164</ArticleId><ArticleId IdType="pubmed">36720629</ArticleId></ArticleIdList></Reference><Reference><Citation>Piras A.M., Grassiri B., Migone C., Zambito Y., Healy A.M., Ehrhardt C., Roncucci P., Ferro B. Aerosolised Phosphodiesterase 3 Inhibitor Enoximone in the Treatment of COVID-19 Pneumonia: In Vitro Evaluations Supporting Clinical Evidence; Proceedings of the Drug Delivery to the Lungs, Edinburgh International Conference Centre and Virtual; Edinburgh, UK. 7–9 December 2022.</Citation></Reference><Reference><Citation>Grassiri B., Cesari A., Balzano F., Migone C., Kali G., Bernkop-Schnürch A., Uccello-Barretta G., Zambito Y., Piras A.M. Thiolated 2-Methyl-β-Cyclodextrin as a Mucoadhesive Excipient for Poorly Soluble Drugs: Synthesis and Characterization. Polymers. 2022;14:3170. doi: 10.3390/polym14153170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14153170</ArticleId><ArticleId IdType="pmc">PMC9370929</ArticleId><ArticleId IdType="pubmed">35956685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Hong S., Tan S.S.K., Peng T., Goh L.Y.H., Lam K.H., Chow K.T., Gokhale R. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies. Molecules. 2022;27:6497. doi: 10.3390/molecules27196497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27196497</ArticleId><ArticleId IdType="pmc">PMC9572940</ArticleId><ArticleId IdType="pubmed">36235038</ArticleId></ArticleIdList></Reference><Reference><Citation>Váradi J., Hermenean A., Gesztelyi R., Jeney V., Balogh E., Majoros L., Malanga M., Fenyvesi É., Szente L., Bácskay I., et al. Pharmacokinetic Properties of Fluorescently Labelled Hydroxypropyl-Beta-Cyclodextrin. Biomolecules. 2019;9:509. doi: 10.3390/biom9100509.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9100509</ArticleId><ArticleId IdType="pmc">PMC6843445</ArticleId><ArticleId IdType="pubmed">31546989</ArticleId></ArticleIdList></Reference><Reference><Citation>Barski P., Surdacki M., Saj A., Wróblewska A., Ornat M., Pawelak A., Pompa D., Jurgiel J., Ermisch V., Hirnle A., et al. Isotonic Saline Nebulization and Lung Function in Children with Mild Respiratory Ailments. Physiol. Res. 2020;69:131–137. doi: 10.33549/physiolres.934394.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.934394</ArticleId><ArticleId IdType="pmc">PMC8604049</ArticleId><ArticleId IdType="pubmed">32228018</ArticleId></ArticleIdList></Reference><Reference><Citation>Petpiroon N., Netkueakul W., Sukrak K., Takahashi K. Development of lung tissue models and their applications. Life Sci. 2023;334:122208. doi: 10.1016/j.lfs.2023.122208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2023.122208</ArticleId><ArticleId IdType="pubmed">37884207</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam M., Ladilov Y. Emerging Role of cAMP/AMPK Signaling. Cells. 2022;11:308. doi: 10.3390/cells11020308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11020308</ArticleId><ArticleId IdType="pmc">PMC8774420</ArticleId><ArticleId IdType="pubmed">35053423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokra D., Mokry J. Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives? Int. J. Mol. Sci. 2021;22:1929. doi: 10.3390/ijms22041929.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041929</ArticleId><ArticleId IdType="pmc">PMC7919656</ArticleId><ArticleId IdType="pubmed">33669167</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes I.G., De Brito C.A., Dos Reis V.M.S., Sato M.N., Pereira N.Z. SARS-CoV-2 and Other Respiratory Viruses: What Does Oxidative Stress Have to Do with It? Oxid. Med. Cell. Longev. 2020;2020:1–13. doi: 10.1155/2020/8844280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8844280</ArticleId><ArticleId IdType="pmc">PMC7757116</ArticleId><ArticleId IdType="pubmed">33381273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>